Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
36°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
0.6991
-0.0135 (-1.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
The trading volume of these stocks is deviating from the norm in today's session.
April 10, 2025
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 09, 2025
Via
Benzinga
The market is filled with gapping stocks in Wednesday's session.
April 09, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Which stocks are moving on Tuesday?
April 08, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Tuesday's session: most active stocks
April 08, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via
Chartmill
Which stocks are experiencing notable movement on Tuesday?
April 08, 2025
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 08, 2025
Via
Benzinga
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
April 08, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 04, 2025
Via
Benzinga
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
March 27, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
March 18, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
March 12, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
March 06, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
March 05, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 10, 2025
Via
Benzinga
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
December 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
November 20, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
November 15, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
November 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
November 12, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 06, 2024
Via
Benzinga
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
November 05, 2024
Via
AB Newswire
Topics
Government
Exposures
Political
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
November 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
S&P 500 Gains 1%; Vimeo Shares Spike Higher
November 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 05, 2024
Via
Benzinga
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
November 05, 2024
Via
Benzinga
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
November 05, 2024
Via
Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
October 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
October 22, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.